Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism.
Featured Articles:
Featured Articles:
- EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
- Does IPSS-R down-staging before transplantation improve the prognosis of patients with Myelodysplastic Neoplasms?
- Increased risk of venous thromboembolism [or VTE] in young and middle-aged individuals with hereditary angioedema: a family study